A number of recent observations have brought into question a possible role for the somatomedins in explaining the growth failure which characterizes chronic renal disease in childhood [1-51. In order to put these findings into perspective, it is necessary first to review the status of these peptides as mediators of growth and the wide variety of techniques which have been used to measure the levels of these substances in serum.
The nature of the somatomedins
The somatomedins are a family of growth-hormone-dependent, insulin-like peptides which have been postulated to mediate the actions of pituitary growth hormone on skeletal tissue. Their exact physiologic role, however, remains the subject of controversy since a convincing demonstration has not yet been made that any of the somatomedins will restore growth when administered to a bypophysectomized animal.
The existence of these peptides was first suggested by the pioneering observations of Salmon and Daughaday in 1957 [6] , that cartilage is not affected by direct exposure to growth hormone itself in vitro, but is responsive to one or more substances which appear in serum after growth hormone administration. This growth-hormone-dependent serum activity was initially called "sulfation factor" because of its capacity to stimulate sulfate incorporation into proteoglycans of cartilage. This action, however, later proved to be but one manifestation of the growth-promoting effect of the "sulfation factor." In cartilage, it also stimulates the synthesis of RNA and DNA as well as collagen and other proteins; in muscle and adipose tissue, it mimics the action of insulin; and, in cell culture, it stimulates DNA synthesis and mitosis in a variety of cell lines.
For these reasons, the constrictive term "sulfation factor" has been replaced by the more general designation "somatomedin" [71.
361 Four peptides have been described which fulfill the definition of a somatomedin: somatomedin-A, somatomedin-D, nonsuppressible insulin-like activity-soluble (NSILA-S), and multiplication-stimulating activity (MSA) [81. Although these four substances are small peptides with molecular weights between 5,500 and 8,500 daltons, it is still unclear whether each of these somatornedins is a different substance or whether some of them may be different names for the same peptide.
The somatomedins constitute only one category in the larger group of peptide growth factors that has been recognized within recent years. There is increasing evidence that these factors collectively play a large role in the hierarchy of growth-regulating mechanisms. The broad spectrum growth factors which stimulate cell division in a wide variety of cell types include fibroblast growth factor, epidermal growth factor, and the somatomedins. Examples of more specialized growth factors which act on highly specific cell types are erythropoietin, nerve growth factor, and thymosine [9] .
Under many circumstances, the concentration of somatomedin in serum accurately reflects growth hormone status and frequently correlates better with linear growth rates of children than do direct measurements of growth hormone itself [10, 111. There are circumstances, however, where the relationship between somatomedin and growth hormone levels are paradoxical. The most striking example of this is in starvation and protein-calorie malnutrition, where growth hormone levels are Daughaday's original assay, which utilized cartilage from hypophysectomized rats, has been modified by many investigators in attempts to improve reproducibility and precision. These modifications have included the use of cartilage from a single hypophysectomized rat [17] and the use of cartilage segments from fasted immature rats [18, 19] . Hall, Holmgren, and Lindahl [20] substituted pelvic leaflets from il-day-old chick embryos for rat cartilage, and Van den Brande and DuCaju [15] developed an assay using uniform pieces of pig rib cartilage. Phillips, Herington, and Daughaday [21] stressed the importance of acquiring cartilage from pigs less than 9 months of age.
Although there is no evidence that any of these bioassays discriminate differentially among the different somatomedins, all of the cartilage bioassays suffer from inherent imprecision and from the fact that a variety of substances present in the serum may exert inhibitory effects on either sulfate or thymidine incorporation into cartilage. Salmon has studied the nature of these inhibitors both in hypophysectomized and starved rats and has found that at least part of the inhibitory material is heatlabile, nondialyzable, and destroyed by trypsin digestion [22] . Van den Brande and DuCajo have suggested that bioassayable somatomedin levels may be falsely depressed by such inhibition in protein calorie malnutrition [151, but Grant et al have disputed this finding and believe somatomedin levels to be authentically low in this condition [12] .
There is now evidence (Furlanetto RW and VanWyk JJ, unpublished data) that the depressed somatomedin levels found in children receiving highdose glucocorticoid therapy are due to a direct depressing effect of the corticosteroids in serum on cartilage tissue. Bioassays based on the uptake of SO4 into cartilage are also subject to serious error if the total concentration of sulfate in serum is not taken into consideration. This is a particularly seriotis source of error in renal disease where the serum sulfate concentration may be markedly elevated [5] . Wiedemann et al [23] have shown that heparin falsely elevates somatomedin levels in cartilage bioassays.
Radioreceptor assays. Each of the four somatomedins has been found to compete with '2I-insulin for binding to the insulin receptor in a variety of cell membranes. In addition, each of the radiolabeled somatomedins hinds to specific somatomedin cell membrane receptors distinct from the insulin receptor. These receptor interactions have served as a basis for competitive membrane-binding assays to measure somatomedin levels in serum. Although radioreceptor assays are not subject to distortion because of inhibitors and variances in sulfate concentration in the serum, there is reason to believe that some of these radioligand-binding assays may measure different populations of substances in serum. In spite of the theoretical advantages over bioassays (lack of influence of inorganic sulfate, steroids, and cartilage inhibitors), discrepancies obtained in different laboratories with the respective radioligands have often been greater than those obtained with bioassays.
Radioimmunoassays. Specific radioimmunoassays have now been developed for NSILA-S and somatomedin-C. Furlanetto et al [24] have reported that the serum values obtained with the radioimmunoassay for somatomedin-C exhibit greater growth hormone dependence than any of the other assays. Whereas by other assay techniques, hypopituitary patients have serum levels 20 to 40% of normal, levels of somatomedin-C by radioimmunoassay are much less than this and are often undetectable. Similarly, patients with acromegaly have much higher serum somatomedin-C levels by radioimmunoassay than do those obtained with any other technique.
The levels of somatomedin-C by radioimmunoassay in protein calorie malnutrition are undetectable until the state of nutrition is improved. This technique has not yet been used to study children with chronic renal failure. somatomedin by bioassay in nine growth-retarded uremic male children before and following renal transplantation. Serum somatomedin levels were corrected for sulfate concentrations in this study. Before transplantation, somatomedin levels were low in all children (in the hypopituitary range). Following renal transplantation, there was a significant linear correlation between growth velocity corrected for bone age and somatomedin levels as well as creatinine clearance. Somatomedin levels after transplantation were not statistically different from the somatomedin levels of eight healthy male control subjects matched for bone age. Growth hormone levels were normal following transpianation.
Phillips et al and Pennisi et al [3, 27] found sulfate concentrations in uremic children to be 7 to 22 times normal before dialysis and 3 to 12 times normal after dialysis. When somatomedin levels were calculated without correction for sulfate, 9 out of 10 children had undetectable levels before dialysis. When these authors corrected somatomedin levels for sulfate content in the serum, somatomedin levels were below the normal range in 4 of 10 children. Following dialysis, corrected somatomedin levels increased an average of 75% and were within the normal range in all. Wiedemann et al have recently suggested that the observed rise in somatomedin following dialysis may be related to heparinization [231. Although Phillips et al [3] also found that heparinization increased somatomedin measurement, they argued that this could only account for 25% of their observed increases in somatomedin levels following dialysis. These authors suggested that dialysis may remove somatomedin inhibitors [281.
The radioreceptor assay for somatomedin has produced somewhat different results in children with chronic renal failure. Arnold et al [291 studied 23 children with varying degrees of chronic renal failure; 15 had glomerular filtration rates less than 50 mllminll.73 m2, and 5 were Ofl hemodialysis. No correlation was found between somatomedin A levels as measured by the radioreceptor assay and gbmerular filtration rates. Somatomedin A levels were higher in children of all ages than they were in adults. Children with renal disease with glomerular filtration rates of less than 50 mllmin had somatomedin A levels that were similar to those of normal children. The five children who were on hemodialysis, however, had somatomedin A levels that were three times those of normal pediatric controls. Children undergoing peritoneal dialysis had normal somatomedin A levels. These authors observed a correlation between somatomedin A levels and caloric intake in uremic and normal children.
The finding of a correlation between somatomedin levels and nutritonal status is reminiscent of the studies of kwashiorkor by Grant et al [12] . Correction of this nutritional deficit in these children resulted in a rise of somatomedin levels (measured by bioassay) to normal.
Somatomedin levels in children with chronic renal failure have thus been found to be low, normal, or high in various laboratories by various assays. Bioassays, even when corrected for sulfate content, have tended to give normal or low values in children with chronic renal failures, whereas radioreceptor assays have tended to give high values. The effect of hemodialysis in removing inhibitors of somatornedin remains to be clarified. It is clear that more work needs to be done regarding the technical aspects of somatomedin measurement. The radioimmunoassay that has recently been developed may improve this technology [24] . The clinician caring for children with growth failure and the clinical investigator had best wait until those with technical expertise in this field resolve these difficulties before drawing firm conclusions as to the level of somatomedin in renal failure associated with growth failure in children.
An area which has received all too little attention is end-organ resistance to the action of growth hormone-dependent (and independent?) somatomedins. The relationship of the assayable somatomedin to its in vivo effect on the target tissue (cartilage, bone) in the promotion of linear growth is unclear. To understand the action of the somatomedins, we must distinguish between their effect on cell proliferation in a biological assay and the effect on differentiated cell functions which are characteristic of the target cells. We must now turn our attention to careful studies of the target tissues.
Summary
The somatomedins are a family of growth hormone-dependent insulin-like peptides which have been postulated to mediate the actions of pituitary growth hormone on skeletal tissue. The somatomedin peptides are part of a larger family of growth factors. Somatomedin has been measured by bioassays, by radioreceptor assays, and recently by a radioimmunoassay. Bioassays are influenced by glucocorticoids, sulfate, heparin, and other inhibitors; radioreceptor assays from different laboratories presently give conflicting results but early experience with the immunoassay is promising. Somatomedin levels are low in hypopituitary states, in malnutrition, and in general when growth hormone is low. Somatomedin's levels in uremia are variously reported. Most bioassays report low values, although the hole of inhibitors is not clear. Values by radioreceptor assays are normal or elevated, but their specificity is unproven. No data are available using radioimmunoassay. No study has addressed end-organ responsivity in uremia.
